COVID-19: In Vitro Diagnostic Testing - (0557)

Cigna covers molecular and antigen SARS‑CoV‑2 diagnostic testing only for symptomatic individuals with known or suspected exposure when ordered/administered by a licensed provider, and covers antibody testing only when prior molecular/antigen results are non‑diagnostic and the antibody result will aid diagnosis of COVID‑19‑related conditions (e.g., MIS, post‑acute sequelae); screening/surveillance, employment/administrative testing, OTC tests, variant/genotyping, surrogate neutralization, and non‑diagnostic devices are excluded. Key requirements: document symptoms/exposure and ordering provider, use appropriate (non‑screening) diagnosis codes, provide prior test results for serology, and ensure CLIA high‑complexity lab certification for high‑throughput testing.

"Molecular or antigen in vitro diagnostic test for SARS-CoV-2 (COVID-19) infection when ALL of the following criteria are met: clinical concern for a symptomatic COVID-19 infection; individual with ..."